<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00395486</url>
  </required_header>
  <id_info>
    <org_study_id>D3560L00061</org_study_id>
    <secondary_id>ROMEO</secondary_id>
    <nct_id>NCT00395486</nct_id>
  </id_info>
  <brief_title>ROMEO (Rosuvastatin in Metabolic syndrOme)</brief_title>
  <official_title>A 6-week, Randomised, Open-label, Parallel Group, Multi-centre Study to Compare the Efficacy of Rosuvastatin 10mg With Atorvastatin 10mg in the Treatment of Metabolic Syndrome Subjects With Raised LDL-C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the effect of rosuvastatin 10mg with
      atorvastatin 10mg after 6 weeks of treatment in the ratio of ApoB/ApoA1 in subjects with
      metabolic syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change From Baseline in Ratio of Apolipoprotein (ApoB/ApoA1) at Week 6</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Samples for evaluation from all investigational sites will be delivered by courier to the central laboratory within 24 hours of blood being drawn. This outcome will be calculated by using the result of ApoB and ApoA1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Reaching Their LDL-C Target Goal</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Based on NCEP ATP III guideline, calculate the percentage of subjects reaching their LDL-C target goal. LDL-C target goals are &lt;70mg/dl, &lt;100mg/dl and &lt;130mg/dl according to their baseline conditions (presence of Coronary heart disease and risk factors and grade of Framingham 10-Year risk).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Reaching Their Low-Density Lipoprotein-C (LDL-C) and Non High-Density Lipoprotein-C (HDL-C) Target Goal</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Based on NCEP ATP III guideline, calculate the percentage of subjects reaching their LDL-C &amp; non HDL-C target goal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change of Glucose Level</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Using laboratory test, mean change of glucose level was investigated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change of Insulin Resistance Using HOMA-R</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>HOMA-R was calculated using insulin and glucose levels derived by laboratory test. The formula is as following: HOMA-R = insulin* glucose/22.5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change of Insulin Resistance Using QUICKI</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>QUICKI was calculated using insulin and glucose levels derived by laboratory test. The formula is as following: QUICKI = 1/[log(insulin) + log(glucose)].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Reduction of Low-Density Lipoprotein-C (LDL-C)</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Calculate the percentage reduction of LDL-C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change of Total Cholesterol (TC)</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Calculate the percentage change of total cholesterol level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change of High-Density Lipoprotein-C (HDL-C)</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Calculate the percentage change of HDL-C level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change of Triglycerides (TG)</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Calculate the percentage change of Triglycerides.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change of Apolipoprotein A1 (ApoA1)</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Calculate the percentage change of Apolipoprotein A1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change of Apolipoprotein B (ApoB)</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Calculate the percentage change of apolipoprotein B</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">258</enrollment>
  <condition>Metabolic Syndrome X</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>10mg</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>10mg</description>
    <arm_group_label>Atorvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of 3 or more of the following criteria;

               -  Abdominal obesity (men &gt;90cm women &gt;80cm)

               -  Triglycerides ≥ 150 mg/dL

               -  HDL-C: men &lt; 40 mg/dL, women &lt; 50 mg/dL

               -  BP ≥130/≥85 mmHg or anti-hypertensive treatment

               -  Fasting blood glucose ≥100 mg dL or anti-diabetic treatment

          -  Elevated LDL-C ;

               -  ≥130 mg/dL to &lt; 220 mg/dL in lipid lowering agent naive subjects

               -  ≥100 mg/dL to &lt; 200 mg/dL in subjects who have taken a lipid lowering drug(s)
                  within 4 weeks of visit 1.

          -  Triglyceride &lt; 500 mg/dL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JoonWoo Bahn, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2006</study_first_submitted>
  <study_first_submitted_qc>November 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2006</study_first_posted>
  <results_first_submitted>June 9, 2009</results_first_submitted>
  <results_first_submitted_qc>May 17, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 16, 2011</results_first_posted>
  <last_update_submitted>June 30, 2011</last_update_submitted>
  <last_update_submitted_qc>June 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>MSD</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>rosuvastatin</keyword>
  <keyword>lipoprotein</keyword>
  <keyword>metabolic syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 613 subjects were enrolled in the study at 13 centres, of whom 258 were randomized to treatment with rosuvastatin (n=132) or atorvastatin (n=126). Subjects were recruited throughout South Korea from September 2006 to June 2008.</recruitment_details>
      <pre_assignment_details>Enrolled patients to be randomized should complete 6-week dietary run-in periods. Also, LDL level should be ≥ 130mg/dl &amp; &lt; 220mg/dl and triglyceride should be &lt; 500mg/dl.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rosuvastatin</title>
          <description>10mg</description>
        </group>
        <group group_id="P2">
          <title>Atorvastatin</title>
          <description>10mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="132">Randomized subjects</participants>
                <participants group_id="P2" count="126">Randomized subjects</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="126">Completed subjects</participants>
                <participants group_id="P2" count="121">Completed subjects</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rosuvastatin</title>
          <description>10mg</description>
        </group>
        <group group_id="B2">
          <title>Atorvastatin</title>
          <description>10mg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="132"/>
            <count group_id="B2" value="126"/>
            <count group_id="B3" value="258"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.5" spread="10.0"/>
                    <measurement group_id="B2" value="60.4" spread="9.0"/>
                    <measurement group_id="B3" value="58.9" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change From Baseline in Ratio of Apolipoprotein (ApoB/ApoA1) at Week 6</title>
        <description>Samples for evaluation from all investigational sites will be delivered by courier to the central laboratory within 24 hours of blood being drawn. This outcome will be calculated by using the result of ApoB and ApoA1.</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>10mg</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>10mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Ratio of Apolipoprotein (ApoB/ApoA1) at Week 6</title>
          <description>Samples for evaluation from all investigational sites will be delivered by courier to the central laboratory within 24 hours of blood being drawn. This outcome will be calculated by using the result of ApoB and ApoA1.</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.40" spread="14.70"/>
                    <measurement group_id="O2" value="-36.50" spread="14.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Reaching Their LDL-C Target Goal</title>
        <description>Based on NCEP ATP III guideline, calculate the percentage of subjects reaching their LDL-C target goal. LDL-C target goals are &lt;70mg/dl, &lt;100mg/dl and &lt;130mg/dl according to their baseline conditions (presence of Coronary heart disease and risk factors and grade of Framingham 10-Year risk).</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>10mg</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>10mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Reaching Their LDL-C Target Goal</title>
          <description>Based on NCEP ATP III guideline, calculate the percentage of subjects reaching their LDL-C target goal. LDL-C target goals are &lt;70mg/dl, &lt;100mg/dl and &lt;130mg/dl according to their baseline conditions (presence of Coronary heart disease and risk factors and grade of Framingham 10-Year risk).</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.20"/>
                    <measurement group_id="O2" value="75.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Reaching Their Low-Density Lipoprotein-C (LDL-C) and Non High-Density Lipoprotein-C (HDL-C) Target Goal</title>
        <description>Based on NCEP ATP III guideline, calculate the percentage of subjects reaching their LDL-C &amp; non HDL-C target goal.</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>10mg</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>10mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Reaching Their Low-Density Lipoprotein-C (LDL-C) and Non High-Density Lipoprotein-C (HDL-C) Target Goal</title>
          <description>Based on NCEP ATP III guideline, calculate the percentage of subjects reaching their LDL-C &amp; non HDL-C target goal.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.80"/>
                    <measurement group_id="O2" value="66.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change of Glucose Level</title>
        <description>Using laboratory test, mean change of glucose level was investigated.</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>10mg</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>10mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change of Glucose Level</title>
          <description>Using laboratory test, mean change of glucose level was investigated.</description>
          <units>Percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" spread="10.10"/>
                    <measurement group_id="O2" value="2.78" spread="13.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change of Insulin Resistance Using HOMA-R</title>
        <description>HOMA-R was calculated using insulin and glucose levels derived by laboratory test. The formula is as following: HOMA-R = insulin* glucose/22.5</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>10mg</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>10mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change of Insulin Resistance Using HOMA-R</title>
          <description>HOMA-R was calculated using insulin and glucose levels derived by laboratory test. The formula is as following: HOMA-R = insulin* glucose/22.5</description>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.00" spread="95.20"/>
                    <measurement group_id="O2" value="50.30" spread="287.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change of Insulin Resistance Using QUICKI</title>
        <description>QUICKI was calculated using insulin and glucose levels derived by laboratory test. The formula is as following: QUICKI = 1/[log(insulin) + log(glucose)].</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>10mg</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>10mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change of Insulin Resistance Using QUICKI</title>
          <description>QUICKI was calculated using insulin and glucose levels derived by laboratory test. The formula is as following: QUICKI = 1/[log(insulin) + log(glucose)].</description>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.27" spread="13.90"/>
                    <measurement group_id="O2" value="-1.03" spread="15.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Reduction of Low-Density Lipoprotein-C (LDL-C)</title>
        <description>Calculate the percentage reduction of LDL-C</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>10mg</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>10mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Reduction of Low-Density Lipoprotein-C (LDL-C)</title>
          <description>Calculate the percentage reduction of LDL-C</description>
          <units>percentage reduction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.50" spread="15.10"/>
                    <measurement group_id="O2" value="-37.90" spread="13.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change of Total Cholesterol (TC)</title>
        <description>Calculate the percentage change of total cholesterol level</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>10mg</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>10mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change of Total Cholesterol (TC)</title>
          <description>Calculate the percentage change of total cholesterol level</description>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.10" spread="11.20"/>
                    <measurement group_id="O2" value="-28.80" spread="10.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change of High-Density Lipoprotein-C (HDL-C)</title>
        <description>Calculate the percentage change of HDL-C level</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>10mg</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>10mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change of High-Density Lipoprotein-C (HDL-C)</title>
          <description>Calculate the percentage change of HDL-C level</description>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.90" spread="16.40"/>
                    <measurement group_id="O2" value="8.20" spread="18.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change of Triglycerides (TG)</title>
        <description>Calculate the percentage change of Triglycerides.</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>10mg</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>10mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change of Triglycerides (TG)</title>
          <description>Calculate the percentage change of Triglycerides.</description>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.20" spread="33.90"/>
                    <measurement group_id="O2" value="-15.10" spread="43.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change of Apolipoprotein A1 (ApoA1)</title>
        <description>Calculate the percentage change of Apolipoprotein A1</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>10mg</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>10mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change of Apolipoprotein A1 (ApoA1)</title>
          <description>Calculate the percentage change of Apolipoprotein A1</description>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.50" spread="12.40"/>
                    <measurement group_id="O2" value="4.20" spread="13.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change of Apolipoprotein B (ApoB)</title>
        <description>Calculate the percentage change of apolipoprotein B</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>10mg</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>10mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change of Apolipoprotein B (ApoB)</title>
          <description>Calculate the percentage change of apolipoprotein B</description>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.50" spread="14.10"/>
                    <measurement group_id="O2" value="-34.60" spread="13.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Rosuvastatin</title>
          <description>10mg</description>
        </group>
        <group group_id="E2">
          <title>Atorvastatin</title>
          <description>10mg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

